SCHEMBL13622642

SCHEMBL13622642

CC(C)(C)OC(=O)N[C@@H](CN1C(=O)c2ccccc2C1=O)C(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.43
MMP1 P03956 1/20 0.43
MMP2 P08253 1/20 0.43
MMP3 P08254 1/20 0.43
MMP9 P14780 1/20 0.43
MMP8 P22894 1/20 0.43
MMP13 P45452 1/20 0.43
MALT1 Q9UDY8 1/20 0.43
KMT2A Q03164 4/20 0.42
AKT1 P31749 1/20 0.42
CTSS P25774 3/20 0.41
CTSK P43235 2/20 0.41
ATM Q13315 1/20 0.41
CTSL P07711 1/20 0.39
CTSB P07858 1/20 0.39
MAPT P10636 1/20 0.39
MEN1 O00255 1/20 0.39
CA12 O43570 1/20 0.39
CA9 Q16790 1/20 0.39
PPARG P37231 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8282957 1.00 ALDH1A1 (0.43) ALDH1A1MMP1MMP2MMP3MMP9
SCHEMBL8178666 1.00 ALDH1A1 (0.43) ALDH1A1MMP1MMP2MMP3MMP9
SCHEMBL12679223 0.88 CTSS (0.43) ALDH1A1MMP1MMP2MMP3MMP9
SCHEMBL13622704 0.86 KMT2A (0.43) ALDH1A1MALT1KMT2AAKT1CTSS
SCHEMBL13632866 0.86 KMT2A (0.43) ALDH1A1MALT1KMT2AAKT1CTSS
SCHEMBL5551910 0.86 CA1 (0.50) ALDH1A1MMP1MMP2MMP3MMP9
SCHEMBL5551903 0.86 CA1 (0.50) ALDH1A1MMP1MMP2MMP3MMP9
SCHEMBL5551909 0.86 CA1 (0.50) ALDH1A1MMP1MMP2MMP3MMP9
SCHEMBL13622658 0.86 NPSR1 (0.44) ALDH1A1KMT2AMAPTMEN1
SCHEMBL8282944 0.86 NPSR1 (0.44) ALDH1A1KMT2AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 US disclosed
US-8809371-B2 2014-08-19 US disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 US disclosed
EP-2589592-A1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF FUJIFILM Corporation (JP) 2013-05-08 EP disclosed
US-7619094-B2 Ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus SCHERING CORPORATION (US) 2009-11-17 US disclosed
US-20070093430-A1 Novel ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus MERCK SHARP & DOHME CORP. 2007-04-26 US disclosed
US-7173057-B2 Ketoamides with cyclic P4'S as inhibitors of NS3 protease of hepatitis C virus SCHERING CORPORATION (US) 2007-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF SYK, CD38, BTK ALDH1A1 1638/4885MMP1 2912/4885MMP2 3749/4885
US-20070093430-A1 Novel ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus PREP, PRSS1, P4HB ALDH1A1 2164/4885MMP1 1672/4885MMP2 945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.